Complement Therapeutics

Complement Therapeutics is an early-stage biotechnology company headquartered in Germany and founded in 2020. The company's focus is on the development of advanced therapeutics for complement-mediated diseases, stemming from pioneering research at the University of Manchester. The company's flagship product, CTx001, is currently under evaluation as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additionally, Complement Therapeutics is also working on other programs to explore therapeutic opportunities for various complement-mediated conditions. Moreover, the company is in the process of developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, designed to enable the quantification of over 30 complement cascade proteins. This innovation aims at enabling more precise diagnosis and disease monitoring. The latest highlight for the company is the €72.00M Series A investment secured on the 17th of April 2023. This round saw participation from prominent investors such as BioGeneration Ventures, Forbion, Cambridge Innovation Capital, GIMV, Hadean Partners, Panakes Partners, and Seroba Life Sciences.